Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1635 1674 4100
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18280126 | METHODS OF MODULATING NEURONAL AND OLIGODENDROCYTE SURVIVAL | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 18431197 | METHODS AND COMPOSITIONS FOR MODULATING APPETITE AND INTAKE OF SODIUM | Final Rejection | California Institute of Technology |
| 18271782 | LIPID NANOPARTICLE SPHERICAL NUCLEIC ACIDS | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 17525541 | ALTERING FLOW CELL SIGNALS | Non-Final OA | ILLUMINA CAMBRIDGE LIMITED |
| 18256805 | REGULATORY ELEMENTS FOR SCHWANN CELL-SPECIFIC GENE EXPRESSION | Final Rejection | Wisconsin Alumni Research Foundation |
| 18542950 | METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18247314 | SNCA IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES | Non-Final OA | Alnylam Pharmaceuticals, Inc |
| 18077271 | RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | Non-Final OA | CITY OF HOPE |
| 18259098 | VIRAL CAPSID PROTEINS WITH SPECIFICITY TO HEART TISSUE CELLS | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18251571 | VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy